| Literature DB >> 21468538 |
Ya-Juan Li1, Jian-Ming Zeng, Shi-Feng Huang, Xiao-Zhong Wang, Shi-Qiao Zhao, Wei-Jun Bai, Wei-Xi Cao, Zong-Gan Huang, Wen-Li Feng.
Abstract
Deregulated activity of the BCR-ABL tyrosine kinase encoded by the Bcr-Abl oncogene represents an important therapeutic target for all the chronic myelogenous leukemia (CML) phases. In this study, we sought to identify targeted PKR activation by Bcr-Abl AS RNA, an anti-sense RNA complementary to the unique mRNA fragments flanking the fusion point of Bcr-Abl, which can be used as an effective anti-leukemia strategy in K562 cells. Moreover, we observed expression of Bcr-Abl AS RNA in K562 cells which resulted in selective apoptosis induction through specific activation of PKR, leading to phosphorylation of eIF2α, global inhibition of protein synthesis, caspase-8 activation and BAX up-regulation. The targeted PKR activation and induced apoptosis were reversed by the PKR inhibitor 2-aminopurine. Taken together, our results indicate that targeted PKR activation led to selective apoptosis induction in K562 cells, which correlated with caspase-8 activity and enhanced expression of BAX.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21468538 DOI: 10.3892/ijmm.2011.666
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101